DK3207941T3 - Fremgangsmåder og sammensætninger på basis af diphtheritoksin-interleukin-3-konjugater - Google Patents

Fremgangsmåder og sammensætninger på basis af diphtheritoksin-interleukin-3-konjugater Download PDF

Info

Publication number
DK3207941T3
DK3207941T3 DK17151480.5T DK17151480T DK3207941T3 DK 3207941 T3 DK3207941 T3 DK 3207941T3 DK 17151480 T DK17151480 T DK 17151480T DK 3207941 T3 DK3207941 T3 DK 3207941T3
Authority
DK
Denmark
Prior art keywords
diphtheritoxin
conjugates
interleukin
methods
compositions based
Prior art date
Application number
DK17151480.5T
Other languages
English (en)
Other versions
DK3207941T6 (da
Inventor
Arthur E Frankel
Original Assignee
Scott & White Memorial Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scott & White Memorial Hospital filed Critical Scott & White Memorial Hospital
Application granted granted Critical
Publication of DK3207941T3 publication Critical patent/DK3207941T3/da
Publication of DK3207941T6 publication Critical patent/DK3207941T6/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/202—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK17151480.5T 2006-09-07 2007-09-07 Fremgangsmåder og sammensætninger baseret på diphtheritoksin-interleukin-3-konjugater DK3207941T6 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84347106P 2006-09-07 2006-09-07
US93277207P 2007-06-01 2007-06-01
EP07837840.3A EP2063907B1 (en) 2006-09-07 2007-09-07 Methods and compositions based on diphtheria toxin-interleukin-3 conjugates

Publications (2)

Publication Number Publication Date
DK3207941T3 true DK3207941T3 (da) 2020-03-30
DK3207941T6 DK3207941T6 (da) 2020-11-09

Family

ID=39157851

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07837840.3T DK2063907T3 (da) 2006-09-07 2007-09-07 Fremgangsmåder og sammensætninger baseret på difteritoksin-interleukin-3-konjugater
DK17151480.5T DK3207941T6 (da) 2006-09-07 2007-09-07 Fremgangsmåder og sammensætninger baseret på diphtheritoksin-interleukin-3-konjugater

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK07837840.3T DK2063907T3 (da) 2006-09-07 2007-09-07 Fremgangsmåder og sammensætninger baseret på difteritoksin-interleukin-3-konjugater

Country Status (17)

Country Link
US (7) US7763242B2 (da)
EP (3) EP3520806B1 (da)
JP (7) JP5550905B2 (da)
AU (1) AU2007293047B2 (da)
CA (5) CA3053981C (da)
CY (2) CY1119654T1 (da)
DK (2) DK2063907T3 (da)
ES (2) ES2646545T3 (da)
FR (1) FR21C1017I2 (da)
HU (2) HUE048356T2 (da)
LT (2) LT3207941T (da)
LU (1) LUC00206I2 (da)
NL (1) NL301103I2 (da)
PL (2) PL2063907T3 (da)
PT (1) PT3207941T (da)
SI (1) SI3207941T1 (da)
WO (1) WO2008030539A2 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1692113T3 (da) 2003-11-14 2018-01-08 Lorus Therapeutics Inc Arylimidazoler og anvendelse heraf som anticancermidler
SI3207941T1 (sl) 2006-09-07 2020-08-31 Scott & White Memorial Hospital Postopki in sestavki na osnovi konjugatov toksina davice-interlevkin-3
US8129341B2 (en) 2008-08-25 2012-03-06 New York University Methods for treating diabetic wounds
EP2352526A1 (en) * 2008-09-19 2011-08-10 Protox Therapeutics Inc. Treating cancer stem cells using targeted cargo proteins
NZ601760A (en) * 2010-02-17 2013-10-25 Csl Ltd Compositions and methods for targeting type 1 interferon producing cells
EP3272352B1 (en) 2010-06-17 2022-04-13 New York University Therapeutic and cosmetic uses and applications of calreticulin
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
US20130224191A1 (en) 2010-08-27 2013-08-29 Robert A. Stull Notum protein modulators and methods of use
BR112013005116A2 (pt) 2010-09-03 2019-09-24 Stem Centrx Inc moduladores e métodos de uso
PE20171143A1 (es) 2010-12-08 2017-08-10 Stem Centrx Inc Nuevos moduladores y metodos para su uso
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
EP3332802A1 (en) 2011-07-06 2018-06-13 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
PE20190658A1 (es) 2012-02-24 2019-05-08 Abbvie Stemcentrx Llc Moduladores y metodos de empleo novedosos
EP3539985A1 (en) 2012-02-24 2019-09-18 AbbVie Stemcentrx LLC Anti sez6 antibodies and methods of use
HUE043851T2 (hu) 2013-02-22 2019-09-30 Abbvie Stemcentrx Llc Anti-DLL3-antitest-PBD konjugátumok és alkalmazásuk
SG11201601424PA (en) 2013-08-28 2016-03-30 Stemcentrx Inc Site-specific antibody conjugation methods and compositions
EP3038634A4 (en) 2013-08-28 2017-10-11 AbbVie Stemcentrx LLC Novel sez6 modulators and methods of use
KR20160058960A (ko) * 2013-10-04 2016-05-25 압토스 바이오사이언시스 인코포레이티드 암을 치료하기 위한 조성물과 방법
US10053511B2 (en) 2013-11-06 2018-08-21 Abbvie Stemcentrx Llc Anti-claudin antibodies and methods of use
AU2014361856A1 (en) 2013-12-12 2016-06-30 Abbvie Stemcentrx Llc Novel anti-DPEP3 antibodies and methods of use
JP2017514143A (ja) 2014-02-21 2017-06-01 アッヴィ・ステムセントルクス・エル・エル・シー メラノーマに使用するための抗ｄｌｌ３抗体および薬物コンジュゲート
BR112016025291A2 (pt) 2014-04-30 2017-12-26 Abbvie Stemcentrx Llc conjugados de anticorpo anti-ptk7-fármaco
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
CA3021098A1 (en) 2016-04-21 2017-10-26 Abbvie Stemcentrx Llc Novel anti-bmpr1b antibodies and methods of use
CN107793481A (zh) * 2016-08-31 2018-03-13 南京传奇生物科技有限公司 一种靶向人cd123的嵌合受体配体及其应用
US11149047B2 (en) 2017-10-30 2021-10-19 Aptose Biosciences, Inc. Aryl imidazoles for treatment of cancer
US20210361744A1 (en) * 2018-04-27 2021-11-25 Stemline Therapeutics, Inc. Methods of Treating an Autoimmune Disease with a Human Interleukin-3 (IL-3)-Diphtheria Toxin Conjugate (DT-IL3)
EP3802834A4 (en) * 2018-05-30 2022-08-03 The Governing Council of the University of Toronto METHODS AND KITS FOR IDENTIFYING A PROTEIN ASSOCIATED WITH RECEPTOR-LIGAND INTERACTIONS
BR112021007945A2 (pt) 2018-10-31 2021-08-03 Stemline Therapeutics, Inc. método de terapia de combinação para tratar neoplasmas mieloproliferativos com um conjugado de toxina de difteria-interleucina-3 humana em combinação com outros agentes
WO2020112642A1 (en) 2018-11-30 2020-06-04 Stemline Therapeutics, Inc. Improved methods of treating myeloproliferative neoplasms with a diphtheria toxin-human interleukin-3 conjugate
EP4061967A1 (en) * 2019-11-21 2022-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for diagnosing and treating chronic myelomonocytic leukemia (cmml)
EP4259103A1 (en) 2020-12-10 2023-10-18 Stemline Therapeutics Inc. Improved lyophilized formulation

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3369466D1 (en) 1982-05-12 1987-03-05 Harvard College Fused genes encoding hybrid proteins, cloning vectors containing them and the use thereof
US5080898A (en) 1982-05-12 1992-01-14 The University Hospital Enzymatically active toxin coupled to a cell-specific ligand
US6022950A (en) 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
WO1991006287A1 (en) 1989-11-06 1991-05-16 Enzytech, Inc. Protein microspheres and methods of using them
DK0517829T4 (da) 1990-03-02 2008-03-03 Boston Medical Ct Corp Forbedrede kimæriske toksiner
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
DE4121547A1 (de) 1991-06-28 1993-01-14 Daimler Benz Ag Mehrschichtisolierfolie
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
DE4140121C2 (de) 1991-12-05 1994-06-30 Manfred Mueller Verfahren zum Herstellen von gefaßten, gegossenen Schmuckstücken
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
AU5965296A (en) * 1995-05-31 1996-12-18 Regents Of The University Of Minnesota Recombinant polypeptide cytotoxins for cancer treatment
US5916597A (en) 1995-08-31 1999-06-29 Alkermes Controlled Therapeutics, Inc. Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent
US5843633A (en) 1996-04-26 1998-12-01 Amcell Corporation Characterization of a human hematopoietic progenitor cell antigen
US20040013664A1 (en) 1997-01-14 2004-01-22 Gentz Reiner L. Tumor necrosis factor receptors 6 alpha & 6 beta
US6004528A (en) 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
CA2393132A1 (en) 1999-12-03 2001-06-07 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Dendritic cell-specific antibodies
AU5003001A (en) 2000-03-06 2001-09-17 Univ Kentucky Res Found Methods to impair hematologic cancer progenitor cells and compounds related thereto
EP1372720A4 (en) 2001-03-02 2006-07-26 Medimmune Inc PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING ANTAGONISTS OF INTEGRIN ALPHA V BETA 3
AU2002322478A1 (en) 2001-03-02 2002-12-16 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
AU2004229501B2 (en) 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
SI3207941T1 (sl) 2006-09-07 2020-08-31 Scott & White Memorial Hospital Postopki in sestavki na osnovi konjugatov toksina davice-interlevkin-3
AU2014201901B2 (en) 2006-09-07 2016-05-05 Scott & White Healthcare Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
US8163279B2 (en) 2007-04-13 2012-04-24 Stemline Therapeutics, Inc. IL3Rα antibody conjugates and uses thereof
WO2013130917A1 (en) 2012-02-29 2013-09-06 Ambrx, Inc. Interleukin-3 polypeptide conjugates their uses

Also Published As

Publication number Publication date
AU2007293047A1 (en) 2008-03-13
WO2008030539A2 (en) 2008-03-13
LTPA2021507I1 (da) 2021-06-10
PL3207941T6 (pl) 2020-11-16
CA2698595C (en) 2016-07-26
CA2698595A1 (en) 2008-03-13
JP6654660B2 (ja) 2020-02-26
CA3153438C (en) 2024-03-12
JP6336500B2 (ja) 2018-06-06
US10259853B2 (en) 2019-04-16
FR21C1017I2 (fr) 2022-04-22
LT3207941T (lt) 2020-04-10
EP2063907B1 (en) 2017-08-09
JP2022065089A (ja) 2022-04-26
US11130792B2 (en) 2021-09-28
JP2010502712A (ja) 2010-01-28
CA3007075A1 (en) 2008-03-13
CA3007075C (en) 2019-10-15
US8470307B2 (en) 2013-06-25
CA3053981C (en) 2022-07-12
JP5902223B2 (ja) 2016-04-13
EP3207941B1 (en) 2019-12-25
DK3207941T6 (da) 2020-11-09
WO2008030539A3 (en) 2009-04-09
PT3207941T (pt) 2020-04-02
FR21C1017I1 (da) 2021-07-02
LUC00206I2 (da) 2022-10-07
LTC3207941I2 (da) 2022-10-10
US9181317B2 (en) 2015-11-10
EP3520806A1 (en) 2019-08-07
JP2024088720A (ja) 2024-07-02
EP3207941A1 (en) 2017-08-23
US20190169251A1 (en) 2019-06-06
SI3207941T1 (sl) 2020-08-31
CA2923381A1 (en) 2008-03-13
CY1123035T1 (el) 2021-09-14
US20220235108A1 (en) 2022-07-28
AU2007293047B2 (en) 2014-01-09
EP2063907A4 (en) 2011-08-31
US7763242B2 (en) 2010-07-27
CA3053981A1 (en) 2008-03-13
NL301103I2 (nl) 2021-08-02
JP2016155830A (ja) 2016-09-01
US20080138313A1 (en) 2008-06-12
EP3520806B1 (en) 2024-03-20
US20160024167A1 (en) 2016-01-28
US20090232767A1 (en) 2009-09-17
US20180022788A1 (en) 2018-01-25
HUE048356T2 (hu) 2020-07-28
NL301103I1 (nl) 2021-06-17
CA3153438A1 (en) 2008-03-13
JP2020079260A (ja) 2020-05-28
ES2781402T7 (es) 2021-06-09
ES2646545T3 (es) 2017-12-14
DK2063907T3 (da) 2017-11-13
JP2018135378A (ja) 2018-08-30
JP5550905B2 (ja) 2014-07-16
HUS2100013I1 (hu) 2021-05-28
EP2063907A2 (en) 2009-06-03
PL3207941T3 (pl) 2020-07-27
ES2781402T3 (es) 2020-09-01
EP3207941B3 (en) 2020-08-19
CY1119654T1 (el) 2019-07-10
US20130315860A1 (en) 2013-11-28
US9631006B2 (en) 2017-04-25
JP2014144967A (ja) 2014-08-14
PL2063907T3 (pl) 2018-06-29

Similar Documents

Publication Publication Date Title
DK3207941T3 (da) Fremgangsmåder og sammensætninger på basis af diphtheritoksin-interleukin-3-konjugater
DK3263589T5 (da) Peptidsekvenser og sammensætninger
DK2570467T3 (da) Sammensætninger af tetrafluorpropen og carbonhydrider
DK2444807T3 (da) Mono- og dinitropyrazolhaptenkonjugater
DK1912671T3 (da) Beta-glucuronid-linker-lægemiddelkonjugater
DK2087002T3 (da) Sammensætninger og fremgangsmåder til binding af sphingosin-1-phosphat
DK2161038T3 (da) Sammensætninger og deres anvendelser rettet mod Huntington
DK2135603T3 (da) Sammensætninger og fremgangsmåder til øgning af insulinsensitivitet
DK2069312T3 (da) Pyridazinonderivater
BRPI0716325A2 (pt) Composição antimicrobianas
DE602007010795D1 (de) Blattsauger und -häcksler
FR2899479B1 (fr) Composition cicatrisante
DK3308788T3 (da) Sammensætninger og fremgangsmåder til modulering af smn2-splejsning
DE602007012130D1 (de) Modifizierte flavin-adenin-dinucleotid-abhängige glucose-dehydrogenase
DK2170827T3 (da) Indolin-2-oner og aza-indolin-2-oner
DE502006006590D1 (de) Biozide zusammensetzungen
DE602007012648D1 (de) Härtbare Zusammensetzung
DE602006010127D1 (de) Härtbare Zusammensetzung
DK3263112T3 (da) Sammensætninger og fremgangsmåder til undertrykkelse af endometriproliferationer
DE602007004820D1 (de) Härtbare Zusammensetzung
DK1920064T3 (da) Sammensætninger og fremgangsmåder til forøgelse af amplifikationseffektiviteten
DK2097068T3 (da) Formuleringer af peg-interferon-alpha-konjugater
DK2334596T3 (da) Ferriphosphatbaseret sammensætning og anvendelse heraf
DK2262525T3 (da) Apoaequorin-holdige sammensætninger og fremgangsmåder til anvendelse af de samme
DK2068935T3 (da) Polymerkonjugater af box-A af HMBG1 og boks-A-varianter af HMBG1